Your shopping cart is currently empty

YE6144 is a prototype IRF5 inhibitor that selectively blocks IRF5 phosphorylation.YE6144 can also inhibit the production of type 1 IFNs (IC50 = 0.09μM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $428 | - | In Stock | |
| 5 mg | $1,280 | - | In Stock | |
| 10 mg | $2,150 | - | In Stock | |
| 25 mg | $3,900 | - | In Stock |
| Description | YE6144 is a prototype IRF5 inhibitor that selectively blocks IRF5 phosphorylation.YE6144 can also inhibit the production of type 1 IFNs (IC50 = 0.09μM). |
| In vitro | Methods: Human HC PBMC and mouse WT splenocytes were treated with YE6144 (1 μM and 3 μM, 30 minutes), and protein expression was detected by Western blotting. Results: YE6144 inhibited the phosphorylation of IRF5 in the above cells. [1] |
| In vivo | Methods: YE6144 (40 mg/kg, subcutaneous injection, single dose) was used to treat NZB/W F1 mice with systemic lupus erythematosus (SLE) and its effects were observed. Results: YE6144 was able to inhibit the progression of autoantibody production in mice. Post-onset treatment also inhibited splenomegaly and renal insufficiency. [1] |
| Synonyms | YE 6144 |
| Molecular Weight | 447.94 |
| Formula | C21H27ClFN7O |
| Cas No. | 3065657-02-2 |
| Smiles | C(=C/C1=CC=C(N=N1)N2CCOCC2)\C=3C=4C(=CC(F)=C(NC[C@H](CC)N)C4)NN3.Cl |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (122.78 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (22.32 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.